ArticleCancers2021

The RXR Agonist MSU42011 Is Effective for the Treatment of Preclinical HER2+ Breast Cancer and Kras-Driven Lung Cancer.

Ana S Leal et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.